Evidence map›Paper›PMID 35666393›Full record

ReviewNeurochemical research2022

Self-assembling Molecular Medicine for the Subacute Phase of Ischemic Stroke.

Takahiro Muraoka, Itsuki Ajioka

Open access · hybridAbstract readReview
In one paragraph

Review in Neurochemical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. The effects of self-assembling peptide on glial cell activation.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Takahiro MuraokaDepartment of Applied Chemistry, Graduate School of Engineering, Tokyo University of Agriculture and Technology, Tokyo, 184-8588, Japan. muraoka@go.tuat.ac.jp.ORCID http://orcid.org/0000-0001-6744-048X
Itsuki AjiokaKanagawa Institute of Industrial Science and Technology (KISTEC), Kanagawa, 243-0435, Japan. iajioka.cbir@tmd.ac.jp.ORCID http://orcid.org/0000-0001-9997-1525
Kanagawa Industrial Technology Center · JPTokyo Medical and Dental University · JP

Funding

Japan Agency for Medical Research and Development JP21jm0210060Japan Society for the Promotion of Science JP20H04528Japan Society for the Promotion of Science JP21H05096
6 · The paper itself

Abstract

Ischemic stroke leads to acute neuron death and forms an injured core, triggering delayed cell death at the penumbra. The impaired brain functions after ischemic stroke are hardly recovered because of the limited regenerative properties. However, recent rodent intervention studies manipulating the extracellular environments at the subacute phase shed new light on the regenerative potency of the injured brain. This review introduces the rational design of artificial extracellular matrix (ECM) mimics using supramolecular peptidic scaffolds, which self-assemble via non-covalent bonds and form hydrogels. The facile customizability of the peptide structures allows tuning the hydrogels' physical and biochemical properties, such as charge states, hydrophobicity, cell adhesiveness, stiffness, and stimuli responses. Supramolecular peptidic materials can create safer and more economical drugs than polymer materials and cell transplantation. We also discuss the importance of activating developmental programs for the recovery at the subacute phase of ischemic stroke. Self-assembling molecular medicine mimicking the ECMs and activating developmental programs may stand as a new drug modality of regenerative medicine in various tissues.

Indexed as

Ischemic StrokeTissue EngineeringExtracellular MatrixHumansHydrogelsMolecular MedicinePeptidesRegenerative MedicineHydrogelsPeptidesArtificial ECMIschemic strokeRegenerationSelf-assembling molecular medicineSubacute phaseSupramolecular peptidic scaffolds

Identifiers

PMID35666393
PMCPMC9463329
OpenAlexW4281893852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.